INTRAVITREAL INJECTION OF BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH REFRACTORY CME

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RABANIKHAH Z.; KIAVASH V.; RAMEZANI ALI REZA; YASERI M.; SOHEYLIAN MASOUD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2009 | Volume:14 | Issue:4 (57) Page(s): 384-393

Download Full-Text

Persian Verion

View:

864

Download:

Cites:

Information Journal Paper

Title

INTRAVITREAL INJECTION OF BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH REFRACTORY CME

Author(s)

Keywords

Not Registered.

Abstract

Purpose: To compare intravitreal bevacizumab (IVB) with intravitreal triamcinolone acetonide (IVT) for treatment of refractory uveitic cystoid macular edema (CME). Methods: In this randomized clinical trial, 31 eyes with uveitic CME were allocated into 2 groups: the IVB group, received one to three injections of 1.25 mg bevacizumab (15 eyes); the IVT group received one to three injections of 2mg triamcinolone (16 eyes). The primary outcome measure was change in best-corrected visual acuity (BCVA) at 36 weeks. Results: Visual acuity improvement as compared to baseline values was meaningful in the IVB group at 12, 24, and 36 weeks and in the IVT group at 24 and 36 weeks. A significant reduction in central macular thickness (CMT) was observed only in the IVT group at week 36 (74.6±108.0pm [P=0.049]). Intergroup analysis however, disclosed no significant difference in any of the outcome measures. By removing the effect of cataracts, IVT had a better improving effect on VA (P=0.007). No significant systemic side effect was observed during the study period. Conclusion: IVB was as effective as IVT in refractory uveitic CME regarding VA improvement. Irrespective of triamcinolone-induced cataract, the effect of IVT may be superior to IVB.

Cites

No record.

References

No record.

Cite

APA: Copy

RABANIKHAH, Z., KIAVASH, V., RAMEZANI, ALI REZA, YASERI, M., & SOHEYLIAN, MASOUD. (2009). INTRAVITREAL INJECTION OF BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH REFRACTORY CME. BINA, 14(4 (57)), 384-393. SID. https://sid.ir/paper/42948/en

Vancouver: Copy

RABANIKHAH Z., KIAVASH V., RAMEZANI ALI REZA, YASERI M., SOHEYLIAN MASOUD. INTRAVITREAL INJECTION OF BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH REFRACTORY CME. BINA[Internet]. 2009;14(4 (57)):384-393. Available from: https://sid.ir/paper/42948/en

IEEE: Copy

Z. RABANIKHAH, V. KIAVASH, ALI REZA RAMEZANI, M. YASERI, and MASOUD SOHEYLIAN, “INTRAVITREAL INJECTION OF BEVACIZUMAB VERSUS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH REFRACTORY CME,” BINA, vol. 14, no. 4 (57), pp. 384–393, 2009, [Online]. Available: https://sid.ir/paper/42948/en

Related Journal Papers